BioSpace News Archive

Nabriva Therapeutics plc announced positive topline results from their Phase 1 clinical trial that assessed the safety and pharmacokinetics (PK) of oral and intravenous (IV) XENLETA® (lefamulin) in adult patients with cystic fibrosis (CF).

Anavex Life Sciences Corp. today reported financial results for its fiscal year ended September 30, 2022.

FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of America 2022 Biotech SMID Cap Virtual Conference on December 8, at 1:05 PM Eastern Time.

XORTX Therapeutics Inc. is pleased to announce the successful screening and enrollment of the last remaining subjects into the XRX-OXY-101 Bridging Pharmacokinetics Study.

GE Healthcare will offer its own brand CT Motion injector, an innovative, multi-dose, syringeless technology developed and manufactured by ulrich medical, to a growing injector market in the U.S.

BrainsWay Ltd. today reported that David Zacut, M.D., BrainsWay’s Chairman of the Board of Directors, and Avner Hagai, an independent Director on BrainsWay’s Board, separately purchased BrainsWay ordinary shares in recent open market purchases.

Providence Therapeutics Holdings Inc. today announced that Aleksandra Pastrak, M.D., Ph.D., chief medical officer of Providence Therapeutics, will deliver a presentation highlighting Phase 2 data on PTX-COVID19-B, the company’s mRNA COVID-19 vaccine candidate, at the World Vaccine & Immunotherapy Congress taking place in San Diego, California on November 28 – December 1, 2022.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) today announced plans to initiate the PRAX-562 Phase 2 EMBOLD study for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEEs), following U.S. Food and Drug Administration (FDA) authorization to proceed with the study as proposed by Praxis, up to the planned maximum dose of 1.0 mg/kg/day.

InspireMD, Inc. today announced a video series, “12 Days of Carotid Stenting,” which will feature leading multidisciplinary vascular specialists discussing the current and future trends in the carotid treatment market.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to study Allocetra™ in patients with advanced solid malignancies.